Peer-reviewed veterinary case report
CyberKnife radiation treatment for brain tumors in dogs
By Carter, Gabrielle L et al.·Published in Journal of veterinary internal medicine·2021·VCA California Veterinary Specialists, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: CyberKnife stereotactic radiotherapy for treatment of primary intracranial tumors in dogs.
- Species:
- dog
Plain-English summary
A group of 59 dogs with primary brain tumors were treated with a specialized type of radiation therapy called CyberKnife. The results showed that dogs had a median survival time of about 738 days after treatment, with some living much longer. The location of the tumor in the brain affected how long dogs lived after treatment, with tumors in the cerebrum generally leading to better outcomes than those in the cerebellum or brainstem. Overall, CyberKnife therapy appears to be a promising option for dogs with brain tumors, potentially offering improved survival compared to traditional radiation therapy.
People also search for: dog brain tumor treatment · CyberKnife for dogs · dog seizure causes · dog intracranial tumor prognosis
Abstract
BACKGROUND: Limited data exist about the use, efficacy, and prognostic factors influencing outcome when CyberKnife is used to treat dogs with intracranial neoplasia. OBJECTIVES: To determine the prognosis and associated prognostic factors for dogs that were imaged, determined to have primary intracranial tumors, and treated with CyberKnife radiotherapy. ANIMALS: Fifty-nine dogs treated with CyberKnife radiotherapy for primary intracranial tumors. METHODS: Retrospective medical record review of cases from January 2010 to June 2016. Data extracted from medical records included signalment, weight, seizure history, tumor location, tumor type (based on imaging), gross tumor volume, planned tumor volume, treatment dates, radiation dose, recurrence, date of death, and cause of death. RESULTS: The median progression-free interval (PFI) was 347 days (range 47 to 1529 days), and the median survival time (MST) was 738 days (range 4 to 2079 days). Tumor location was significantly associated with PFI when comparing cerebrum (median PFI 357 days; range 47-1529 days) versus cerebellum (median PFI 97 days; range 97-168 days) versus brainstem (median PFI 266 days; range 30-1484 days), P = .03. Additionally, the presumed tumor type was significantly associated with MST (P < .001). CONCLUSIONS AND CLINICAL IMPORTANCE: Use of Cyberknife and SRT might improve MST, compared with RT, in dogs with intracranial neoplasia.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33755255/